Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic pr...

por Dhanasiri, Sujith
Publicado 2019

The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q

por Lee, Dawn, Brereton, Nic, Dhanasiri, Sujith, Kulasekararaj, Austin
Publicado 2018

Chart review across EU5 in MM post-ASCT patients

por Ashcroft, John, Judge, Davneet, Dhanasiri, Sujith, Taylor-Stokes, Gavin, Middleton, Chloe
Publicado 2018

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

por Schey, Steve, Montero, Luis Felipe Casado, Stengel-Tosetti, Chloe, Gibson, Craig J., Dhanasiri, Sujith
Publicado 2017

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment

por Uyl‐de Groot, Carin A., Ramsden, Rachel, Lee, Dawn, Boersma, Janneke, Zweegman, Sonja, Dhanasiri, Sujith
Publicado 2020

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy

por Jackson, Graham, Galinsky, Jayne, Alderson, David E. C., D'Souza, Vijay K., Buchanan, Vanessa, Dhanasiri, Sujith, Walker, Simon
Publicado 2019

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNEC...

por Abonour, Rafat, Rifkin, Robert, Ailawadhi, Sikander, Lee, Hans C., Gasparetto, Christina, Wagner, Lynne, Durie, Brian, Hardin, James, Terebelo, Howard, Narang, Mohit, Toomey, Kathleen, Tang, Yuexin, Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang, Jagannath, Sundar
Publicado 2023